From a cellular pharmacy viewpoint, Relafen 750 represents a intricate case study. Its mechanism of action involves the targeted inhibition of cyclooxygenase enzymes, specifically COX-2 , although with a level of lack of specificity compared to newer agents. This leads to a decrease of prostaglandin synthesis, ultimately alleviating inflammation… Read More